Novartis signs up to $5.2 billion licensing deal with Argo Biopharmaceutical for heart drugs
Sept 3 (Reuters) - Swiss drugmaker Novartis NOVN.S has signed a licensing and options deal with Argo Biopharmaceutical for up to $5.2 billion to gain access to its experimental cardiovascular drugs, the privately held biotech said on Wednesday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Intel Better-Than-Expected Earnings Released, Stock Surges 20% After-Hours, AI Computing Power Enters CPU Moment?

Nebius Stock: Can This AI Infrastructure Play Really Double in 2026?

Semiconductor Sector Continues to Rise, Should Retail Investors Buy Intel or AMD?
Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Tradingkey







